Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.
Advertisement

Related Content

Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges
Regeneron/Bayer Announce Positive VEGF Trap-Eye Data In A Second Eye Disease
Regeneron/Bayer Announce Positive VEGF Trap-Eye Data In A Second Eye Disease
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee

Topics

Advertisement
UsernamePublicRestriction

Register

PS004699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel